Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Eledon Pharmaceuticals Inc ELDN

Healthcare Biotechnology
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular... see more

Recent & Breaking News (NDAQ:ELDN)

Eledon Pharmaceuticals Receives FDA Clearance of IND Application to Evaluate Tegoprubart for the Prevention of Rejection in Kidney Transplant Recipients

GlobeNewswire August 1, 2022

Eledon Pharmaceuticals Announces the First Patient Dosed in Phase 1b Trial Evaluating Tegoprubart in Kidney Transplantation

GlobeNewswire July 18, 2022

Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire June 10, 2022

Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Pancreatic Islet Cell Transplantation

GlobeNewswire June 9, 2022

Eledon Pharmaceuticals to Present at the Jefferies Healthcare Conference

GlobeNewswire June 2, 2022

Eledon Announces Positive Topline Results from Phase 2a Trial of Tegoprubart Demonstrating Safety, Target Engagement, and Biomarker Response in Patients Living with Amyotrophic Lateral Sclerosis

GlobeNewswire May 31, 2022

Eledon Pharmaceuticals Reports First Quarter 2022 Operating and Financial Results

GlobeNewswire May 12, 2022

Eledon Pharmaceuticals Announces First Patient Dosed in Phase 2a Trial Evaluating Tegoprubart in IgA Nephropathy

GlobeNewswire May 9, 2022

Eledon Pharmaceuticals to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022

GlobeNewswire May 5, 2022

Eledon Pharmaceuticals to Participate in LifeSci Partners Immunology & Inflammation Symposium

GlobeNewswire May 3, 2022

Eledon Pharmaceuticals to Participate in 18th Annual Noble Capital Markets Investor Conference

GlobeNewswire April 18, 2022

Eledon to Host Virtual R&D Day on Thursday, April 28, 2022

GlobeNewswire April 14, 2022

Eledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Operating and Financial Results

GlobeNewswire March 24, 2022

Eledon Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 24, 2022

GlobeNewswire March 17, 2022

Eledon Pharmaceuticals Provides Corporate Update and 2022 Outlook

GlobeNewswire February 14, 2022

Eledon Pharmaceuticals to Participate in 11th Annual SVB Leerink Global Healthcare Conference

GlobeNewswire February 8, 2022

Eledon Pharmaceuticals to Participate in January 2022 Investor Conferences

GlobeNewswire December 27, 2021

Eledon Pharmaceuticals Reports Third Quarter 2021 Operating and Financial Results

GlobeNewswire November 11, 2021

Eledon Pharmaceuticals CEO David-Alexandre C. Gros, M.D., to Present at CareDx Virtual Transplant Innovation Day during ASN Kidney Week 2021

GlobeNewswire November 4, 2021

Eledon Pharmaceuticals Announces Participation in November Conferences

GlobeNewswire November 4, 2021